U.S. markets closed

Gene Biotherapeutics, Inc. (CRXM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0500-0.0003 (-0.50%)
At close: 3:33PM EDT
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Currency in USD

Valuation Measures

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 4/7/2021
Current
Market Cap (intraday) 5
1.42M
Enterprise Value 3
1.42M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
137.13
Price/Book (mrq)
3.36
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 7
-0.47

Trading Information

Stock Price History

Beta (5Y Monthly) 1.29
52-Week Change 3-68.75%
S&P500 52-Week Change 349.51%
52 Week High 30.1600
52 Week Low 30.0200
50-Day Moving Average 30.0441
200-Day Moving Average 30.0468

Share Statistics

Avg Vol (3 month) 3495.24k
Avg Vol (10 day) 3357k
Shares Outstanding 514.37M
Implied Shares Outstanding 6N/A
Float 9.69M
% Held by Insiders 132.61%
% Held by Institutions 10.00%
Shares Short (Dec 30, 2013) 4150.25k
Short Ratio (Dec 30, 2013) 41.03
Short % of Float (Dec 30, 2013) 42.47%
Short % of Shares Outstanding (Dec 30, 2013) 41.71%
Shares Short (prior month Nov 28, 2013) 4448.45k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:20
Last Split Date 3Jul 17, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2016
Most Recent Quarter (mrq)Mar 30, 2017

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-758.60%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -3.04M
Net Income Avi to Common (ttm)-3.85M
Diluted EPS (ttm)-0.2850
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)176.37k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)1.05M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.05
Book Value Per Share (mrq)-0.26

Cash Flow Statement

Operating Cash Flow (ttm)-2.52M
Levered Free Cash Flow (ttm)-1.47M